Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

LRRK2 expression is enriched in the striosomal compartment of mouse striatum.

Mandemakers W, Snellinx A, O'Neill MJ, de Strooper B.

Neurobiol Dis. 2012 Dec;48(3):582-93. doi: 10.1016/j.nbd.2012.07.017. Epub 2012 Jul 29.

PMID:
22850484
2.

Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

West AB, Cowell RM, Daher JP, Moehle MS, Hinkle KM, Melrose HL, Standaert DG, Volpicelli-Daley LA.

J Comp Neurol. 2014 Aug 1;522(11):2465-80. doi: 10.1002/cne.23583. Epub 2014 Apr 12.

3.

(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.

Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL.

Neurobiol Dis. 2014 Aug;68:190-9. doi: 10.1016/j.nbd.2014.04.021. Epub 2014 May 14.

PMID:
24830390
4.

Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.

Han BS, Iacovitti L, Katano T, Hattori N, Seol W, Kim KS.

Neurosci Lett. 2008 Sep 19;442(3):190-4. doi: 10.1016/j.neulet.2008.06.086. Epub 2008 Jul 10.

5.

The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.

Davis MI, Crittenden JR, Feng AY, Kupferschmidt DA, Naydenov A, Stella N, Graybiel AM, Lovinger DM.

PLoS One. 2018 Feb 21;13(2):e0191436. doi: 10.1371/journal.pone.0191436. eCollection 2018.

6.

Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.

Higashi S, Moore DJ, Colebrooke RE, Biskup S, Dawson VL, Arai H, Dawson TM, Emson PC.

J Neurochem. 2007 Jan;100(2):368-81. Epub 2006 Nov 13.

7.

Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.

Mikhail F, Calingasan N, Parolari L, Subramanian A, Yang L, Flint Beal M.

Hum Mol Genet. 2015 Jun 15;24(12):3545-56. doi: 10.1093/hmg/ddv105. Epub 2015 Mar 24.

PMID:
25804954
8.

Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.

Giesert F, Hofmann A, Bürger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W.

PLoS One. 2013 May 10;8(5):e63778. doi: 10.1371/journal.pone.0063778. Print 2013.

9.

Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.

Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B.

Neurosci Lett. 2013 Aug 9;549:57-62. doi: 10.1016/j.neulet.2013.05.034. Epub 2013 May 28.

10.

Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.

Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH.

Neurobiol Dis. 2011 Mar;41(3):706-16. doi: 10.1016/j.nbd.2010.12.008. Epub 2010 Dec 16.

11.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
12.

A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.

Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ.

Neuroscience. 2007 Jul 29;147(4):1047-58. Epub 2007 Jul 3.

PMID:
17611037
13.

Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.

Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC.

Brain Res. 2007 Jun 25;1155:208-19. Epub 2007 Apr 19.

PMID:
17512502
14.

Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.

Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M.

Neuroscience. 2006;139(3):791-4. Epub 2006 Feb 28.

PMID:
16504409
15.

Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.

Gillardon F, Schmid R, Draheim H.

Neuroscience. 2012 Apr 19;208:41-8. doi: 10.1016/j.neuroscience.2012.02.001. Epub 2012 Feb 7.

PMID:
22342962
16.

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.

Zhao Y, Keshiya S, Atashrazm F, Gao J, Ittner LM, Alessi DR, Halliday GM, Fu Y, Dzamko N.

Neurobiol Dis. 2018 Dec;120:76-87. doi: 10.1016/j.nbd.2018.09.003. Epub 2018 Sep 5.

17.

Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.

Westerlund M, Ran C, Borgkvist A, Sterky FH, Lindqvist E, Lundströmer K, Pernold K, Brené S, Kallunki P, Fisone G, Olson L, Galter D.

Mol Cell Neurosci. 2008 Dec;39(4):586-91. doi: 10.1016/j.mcn.2008.08.001. Epub 2008 Aug 27.

PMID:
18790059
18.

Distribution of PINK1 and LRRK2 in rat and mouse brain.

Taymans JM, Van den Haute C, Baekelandt V.

J Neurochem. 2006 Aug;98(3):951-61. Epub 2006 Jun 12.

19.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

20.

Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease.

Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, Galter D.

Neuroscience. 2008 Mar 18;152(2):429-36. doi: 10.1016/j.neuroscience.2007.10.062. Epub 2008 Jan 10.

PMID:
18272292

Supplemental Content

Support Center